drugset / Trial / NCT05709314
A Study of AMDX-2011P in Participants With CAA
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
Timeline
- Start
- 2024-07-09
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMDX-2011P | Diagnostic / imaging agent | 100 mg | Intravenous |